Pathkey has entered a master collaboration agreement (MCA) with Armstrong Clinical, a clinical development consultancy in Melbourne, Australia.
This partnership aims to leverage Pathkey’s predictive AI technology with Armstrong Clinical’s experience in early-phase study design to optimise trial success rates from the earliest stages.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The collaboration intends to improve clinical development outcomes by mitigating costly study amendments, cut expenditure, and expedite market entry for new therapies.
The initiative aims to offer benefits throughout the life sciences sector. For biotech and research sponsors, the combination of Armstrong Clinical’s study design expertise and Pathkey’s analytics is expected to deliver higher confidence in trial plans and decrease delays.
Investors will experience capital efficiency and increased transparency, with earlier assessment of technical and regulatory risks. Health systems and regulators may benefit from stronger evidence supporting trial approvals, and patients could gain quicker access to effective and safe therapies, stated the companies.
Pathkey executive chairman Damon Rasheed said: “The earliest stages of clinical development often determine whether a therapy ever reaches patients. Armstrong Clinical’s human expertise and strength in early-phase strategy is the perfect complement to Pathkey’s predictive AI technology.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Through this partnership, we look forward to helping sponsors design smarter, more resilient studies from the beginning – improving their probability of success across the entire development lifecycle.”
Armstrong Clinical provides strategic consulting services in clinical development planning, early-phase trial design, and regulatory strategy.
Armstrong Clinical founder Dr Bradley Joblin said: “Our purpose has always been to help our clients translate research into meaningful clinical and commercial outcomes.
“Partnering with Pathkey supports this goal by bringing our process a new layer of data-driven intelligence. We expect this to deliver our clients greater certainty, efficiency and confidence in their early-phase strategy.”
Under the agreement, the companies will collaborate on projects for biopharma, medtech, and research clients globally. Key priorities include early-phase (Phase I/IIa) study design, AI-powered feasibility analysis, risk assessment, protocol benchmarking, and enhancing Australia’s competitiveness in early-stage clinical trials.
